This article, written with co-authors Bruce H. Kobayashi, Joshua D. Wright, and Douglas H. Ginsburg, examines the economics of litigation and settlement of patent disputes arising from Paragraph IV Abbreviated New Drug Application (ANDA) filings under the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) within the framework set out in Actavis.
Merger Enforcement Guidelines Review: Comments on algorithms for merger review
CRA’s Dr. Alex Arsenault recently submitted comments to the Canadian Competition Bureau’s review of Merger Enforcement Guidelines (MEGs). Dr. Arsenault’s...